Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide

Annals of Hematology

Volumn 92, Issue 12, 2013, Pages 1711-1712

  Kato, Hiroki ^a,b   Onishi, Yasushi ^a   Okitsu, Yoko ^a   Katsuoka, Yuna ^a   Fujiwara, Tohru ^a   Fukuhara, Noriko ^a   Ishizawa, Kenichi ^a   Takagawa, Masanori ^b   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN G; LENALIDOMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; BACKACHE; BONE LESION; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHRONIC DRUG ADMINISTRATION; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

CLARITHROMYCIN; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84888132000     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1761-x     Document Type: Letter

References (8)

1. Morris TC, Kettle PJ, Drake M, Jones FC, Hull DR, Boyd K, Morrison A, Clarke P, O'Reilly P, Quinn J (2008) Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol 143(3):349-354. doi: 10.1111/j.1365-2141.2008.07360.x
2. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M (2008) BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111(3):1101-1109. doi: 10.1182/blood-2007-05-090258
3. Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R (2013) BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121(11):1982-1985. doi: 10.1182/blood-2012-08-448563
4. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R (2010) Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 85(9):664-669. doi: 10.1002/ajh.21777
5. Morris TC, Ranaghan L, Morrison J, Northern Ireland Regional Haematology Group (2001) Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol 18(1):79-84. doi: 10.1385/MO:18:1:79
6. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH (2000) Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118(6):1826-1827
7. Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, Leung DY (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87(6):501-505. doi: 10.1016/S1081-1206(10)62264-8
8. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44(3):279-304